In celebration of Ophthalmology Times ' 50th anniversary, we asked leading experts in the field, in a perfect world, if they ...

Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.

Ollin Biosciences has launched with $100 million in series A financing led by Arch Venture Partners, Mubadala Capital, and ...